Why the study?
The population-level trade-off between stroke prevention and OAC-related major bleeding across different AF types and OAC strategies remains uncertain, and large randomized trials to address this are costly and time-consuming.
Does systematic AF screening with screening-triggered OAC or rhythm-guided 'pill-in-pocket' OAC improve the risk-benefit balance between stroke reduction and major bleeding compared to no screening or continuous OAC in virtual populations with atrial fibrillation?
Does systematic AF screening with screening-triggered OAC or rhythm-guided 'pill-in-pocket' OAC improve the risk-benefit balance between stroke reduction and major bleeding compared to no screening or continuous OAC in virtual populations with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
This virtual clinical trial model demonstrates that systematic screening-initiated OAC yields a net benefit primarily in patients with CHA2DS2-VA ≥4, while rhythm-guided 'pill-in-pocket' OAC may reduce bleeding risk compared to continuous OAC in high-bleeding-risk patients without increasing stroke or mortality.
Background: Oral anticoagulation (OAC) reduces stroke risk in patients with atrial fibrillation (AF), and screening can enable earlier AF detection and OAC initiation. However, the population-level trade-off between stroke prevention and OAC-related major bleeding for different types of AF and OAC therapy remains uncertain, and large randomized trials to resolve this are costly and time-consuming. Methods: A state-transition Markov-like model was developed to: 1) simulate the lifetime course of AF, stroke, major bleeding, and death in different virtual populations; 2) quantify benefits (stroke reduction) and harms (major bleeding) of systematic AF screening with screening-triggered OAC across CHA2DS2-VA scores; and 3) compare rhythm-guided, time-delimited ("pill-in-pocket") OAC with continuous OAC. Results: The model synthesized information from multiple clinical sources and reproduced stroke and bleeding incidence across clinical scenarios. At CHA?DS?-VA=2, long-term continuous rhythm monitoring (LT-CRM) with OAC lowered stroke risk (HR, 0.92 [95%CI, 0.88-0.96]) but raised bleeding risk (HR, 1.17 [95%CI, 1.07-1.27]) versus no screening. Time-to-benefit was shorter than time-to-harm for CHA?DS?-VA?4, but longer for CHA?DS?-VA=0. Pill-in-pocket OAC vs continuous OAC showed no difference in stroke/mortality (HR, 1.03, 95%CI [0.91-1.16]) but lower bleeding risk (HR, 0.81, 95%CI: 0.68-0.96]) in patients with elevated bleeding risk, but not at baseline. Sensitivity analyses revealed that the risk-benefit profiles of screening or pill-in-pocket OAC strategy further depend on OAC adherence and bleeding risks. Conclusions: Our model highlights a trade-off between stroke reduction and bleeding for systematic screening-initiated OAC, with net benefit for CHA?DS?-VA?4. We provide the first virtual implementation of an ongoing rhythm-guided OAC trial, showing that pill-in-pocket OAC may lower bleeding risk compared to continuous OAC, highlighting the potential of virtual clinical trials to guide clinical trial design.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) studied Atrial fibrillation. Systematic AF screening with screening-triggered OAC and pill-in-pocket OAC vs. No screening or continuous OAC was evaluated on Stroke risk (at CHA2DS2-VA=2 for LT-CRM with OAC vs no screening) (HR 0.92, 95% CI 0.88-0.96).
Synapse has enriched 10 related papers. Consider them for comparative context: